Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX - Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $12.00 target price on the stock.
Several other equities research analysts have also recently weighed in on IMRX. Chardan Capital reiterated a "buy" rating and issued a $13.00 target price on shares of Immuneering in a research note on Wednesday, January 8th. Morgan Stanley downgraded Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th.
Check Out Our Latest Research Report on IMRX
Immuneering Price Performance
Shares of NASDAQ IMRX traded down $0.05 during trading hours on Friday, hitting $1.69. 112,922 shares of the stock were exchanged, compared to its average volume of 2,394,433. Immuneering has a one year low of $1.00 and a one year high of $3.83. The company's 50 day moving average is $1.78 and its 200 day moving average is $2.01. The firm has a market capitalization of $52.47 million, a P/E ratio of -0.86 and a beta of -0.32.
Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.16). Research analysts anticipate that Immuneering will post -1.86 earnings per share for the current fiscal year.
Institutional Trading of Immuneering
Several institutional investors have recently made changes to their positions in IMRX. HighTower Advisors LLC lifted its stake in Immuneering by 21.4% during the third quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock worth $132,000 after purchasing an additional 9,400 shares during the period. Corsair Capital Management L.P. acquired a new position in shares of Immuneering in the 3rd quarter worth approximately $25,000. Two Sigma Investments LP lifted its position in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock worth $111,000 after buying an additional 10,126 shares during the period. Tang Capital Management LLC acquired a new stake in Immuneering in the 4th quarter valued at $27,000. Finally, Southport Management L.L.C. grew its position in Immuneering by 4.9% in the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock valued at $473,000 after acquiring an additional 10,000 shares during the period. 67.65% of the stock is currently owned by institutional investors and hedge funds.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Articles
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
